Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $639 | In Stock | |
5 mg | $1,370 | In Stock | |
25 mg | $2,230 | In Stock | |
50 mg | $2,780 | In Stock | |
100 mg | $3,700 | In Stock |
Description | Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes. |
In vitro | METHODS: A comparative dose-response study of PPARγ and PPARα was performed using Ragaglitazar (NNC-61-0029) (0.1, 1, 10, 100 nM). RESULTS Ragaglitazar (NNC-61-0029) showed significant activation of both isoforms. Ragaglitazar showed weaker potency against PPARγ (EC50=324 nm) and more potent activation of PPARα (EC50=270 nm). [1] |
In vivo | METHODS: SD rats fed a high-fat diet were treated with Ragaglitazar (NNC-61-0029) (0.1, 0.3, 1, 10, 30 mg/kg) to observe the improvement of blood lipid levels in rats. RESULTS Rats showed a dose-dependent improvement in plasma lipid levels, and plasma Apo CIII levels were significantly reduced in ragaglitazar (10 mg/kg) (P<0.05). [1] |
Alias | NNC61-0029, NNC-61-0029, NNC 61-0029, NN-622, NN 622, (-)-DRF-2725 |
Molecular Weight | 419.47 |
Formula | C25H25NO5 |
Cas No. | 222834-30-2 |
Smiles | C(COC1=CC=C(C[C@H](OCC)C(O)=O)C=C1)N2C=3C(OC=4C2=CC=CC4)=CC=CC3 |
Relative Density. | 1.241 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (119.2 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.